What US Fragrance Brands Expect from Private Label Manufacturers

Use this supplier due-diligence scorecard to compare evidence for a defined US cosmetic-fragrance project. A buyer requirement is not automatically a manufacturer promise. Verify actual scope, roles, production commitments and documents before awarding the project.

1. Superior Fragrance Quality and Olfactory Consistency

Agree the approved sample, final formula/package and sensory acceptance criteria. Review how the supplier controls materials, process changes and batch release rather than assuming perfect uniformity.

• Confirm the availability and rights for any proposed scent direction and review its actual intended-use conformity information.
• Review material controls, change records and batch acceptance evidence; no sourcing process guarantees perfect uniformity.
• Agree a final-formula/package stability plan; accelerated observations alone do not establish shelf life or all storage performance.
• Separate qualified safety review from claim-specific wear evidence; a generic skin test does not establish all-day performance.

2. Defined US Regulatory Roles and Evidence

Assign responsibilities among the manufacturer, brand/responsible person and qualified reviewers. Confirm applicable MoCRA registration/listing and exemptions, safety substantiation, adverse-event and label duties, plus relevant state and channel obligations. A supplier cannot simply assume all legal responsibilities by providing a document pack. See FDA MoCRA and registration/listing guidance, checked 10 October 2026.

• Agree ingredient/label and relevant allergen information for authorized review, with appropriate confidentiality controls and exact channel requirements.
• Agree applicable batch-release, hazard and transport records; an SDS is not automatically a new per-batch document.
• Review the applicable fragrance conformity information, amendment/version, intended use and scope; do not assume a fixed amendment proves current global safety.
• Guidance on claims substantiation to avoid “therapeutic” language that would turn a cosmetic fragrance into a regulated drug.

3. Confirmed Customization and Minimums

Confirm what can be customized and the actual order/component minimums. LAEYO’s owner-confirmed perfume reference is 1,000 bottles; no 50–100-unit production program, ready-stock scent or approved mixed-SKU allocation is established here.

• Use a written quantity proposal with separate order, scent, bottle and decoration constraints; no 50–100-unit pilot is established.
• Define formulation responsibilities, revision limits and qualified review rather than presuming an all-inclusive turnkey service.
• Confirm whether packaging sourcing/development is in-house or external, which components are available and what validation is needed.
• Agree design scope and approval responsibilities; a premium appearance is an objective to evaluate, not a guaranteed result.

4. Transparent Project Management and Supply Chain Visibility

Agree a named contact, communication method, milestones and escalation path. Location, language support and update frequency must be confirmed, not inferred from the target market.

• Clear, written timelines shared upfront, covering everything from lab approval to packaging delivery and final QC release.
• Agree update frequency and escalation triggers for material, approval or production risks.
• Confirm the actual project contact’s location, language and working hours; no US-based project manager is established here.
• Agree approved-reference and retention-sample controls, access and legally/contractually reviewed retention periods.

5. Evidence Behind Timing and Production Proposals

Ask for a realistic milestone plan and the evidence behind the proposed production quantity. Sample development, validation, filling and replenishment are separate commitments; no rush or scale-up capability is assumed.

• Obtain a milestone plan based on the actual formula, revision scope, validation and component availability.
• Confirm reorder minimums, component stock, approval requirements and realistic replenishment dates; no under-two-week promise is established.
• Request evidence supporting the proposed batch size and change/scale-up controls; no hundreds-to-thousands capacity guarantee is assumed.
• Confirm fulfillment services separately and validate the actual filled shipping configuration for the selected route and channel.

Use the scorecard below to connect each requirement with a specific dated record and unresolved question. Mark whether work is performed in-house, subcontracted or only assisted.

Score only the evidence actually reviewed

Proposed scoring: 0 = absent; 1 = incomplete or unclear scope; 2 = relevant evidence reviewed; 3 = relevant evidence checked against its issuer or a suitable independent record where appropriate. Keep safety/legal gaps as release blockers regardless of the commercial total. This is a blank review tool, not a completed supplier audit.

Use the factory capability page, quality-control and sample-consistency page and certifications and compliance page as starting points for questions. Their existence does not validate a certificate, perfume-specific capacity or completed test. Request readable, product/site-specific evidence before assigning a score.

The company’s published process-image library shows cosmetics compounding vessels, laboratory weighing and prototype preparation, gift-box assembly and packaging equipment. These images document the pictured activities; they do not establish perfume-specific line capacity, test results or a named customer’s production outcome. Use them alongside the document previews linked above when defining the evidence still required for this project.

For US role review, identify the facility owner/operator responsible for applicable registration and biennial renewal, and the manufacturer, packer or distributor named on the label as the responsible person for applicable product listing and annual updates. Record the basis of any exemption instead of assuming a small-business exemption. The responsible person also needs safety-substantiation records and a process for serious adverse-event reporting within 15 business days. FDA does not prescribe a universal cosmetic test panel. FDA’s registration/listing clarification confirms that these processes are neither product approval nor an FDA compliance certificate. Use the FDA MoCRA and registration/listing sources above to assign each duty.

Frequently Asked Questions

What certifications should I look for in a US-focused fragrance manufacturer?
Review the relevance, holder, site, activity scope, validity and verification route of any claimed certificate or audit. IFRA information is separate from finished-product safety and legal compliance. Do not import a medical-device audit program such as MDSAP into a perfume checklist; assess any retailer-requested social or quality audit on its actual scope. No particular certificate is established for this project here.

How long does it take to go from a fragrance brief to a finished product?
Confirm project-specific dates for samples, revisions, final-product evidence, artwork, components, filling, release and shipment. Owner-confirmed sample R&D is about three days excluding communication, confirmation and transport. It is not a six-to-ten-week launch or a four-to-five-week rush promise.

What information do I need to provide to get an accurate quote?
Be ready to share your target product category (Eau de Parfum, body mist, candle, etc.), desired scent direction or reference, approximate order quantity, packaging requirements (bottle type, cap, box), and your launch timeline. The more detail you give, the more precise the pricing and lead time.

Can I develop a custom scent at a smaller quantity?
Discuss the intended development scope and written production proposal. LAEYO’s perfume MOQ reference is 1,000 bottles; scent/component allocation and any other-format minimums require confirmation. Do not rely on an industry example of 50 units as a factory offer.

What happens if a sample fails stability or compatibility review?
Hold approval, record the observed failure and investigate possible causes. Agree corrective options, revision costs and a new evidence plan before accepting a changed formula or package. No test plan guarantees every failure will be detected before production.

Compare relevant evidence and unresolved risks before selection. To discuss your project brief and due-diligence requirements, Request a Quote.